RealTime Dynamix™: Crohn’s Disease US Q2
Crohn’s Disease (CD) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. Theintroduction of biologics has changed the face of treatment for moderateto-severe CD patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the CD landscape. […]
RealTime Dynamix™: Psoriatic Arthritis US Q2
The already highly dynamic US market for Psoriatic Arthritis (PsA) with the recent entrance of Celgene’s Otezla and Novartis’ Cosentyx is set to go up another level of complexity with Eli Lilly’s Taltz and AstraZeneca/Valeant’s brodalumab close to approval dates and line extensions being sought for Pfizer’s Xeljanz and Simponi Aria from Janssen. RealTime Dynamix: […]
RealTime Dynamix™: Hyperkalemia (Neph) US Q2
The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. […]
RealTime Dynamix™: Ulcerative Colitis US Q2
Ulcerative Colitis (UC) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. The introduction of biologics has changed the face of treatment for moderateto-severe UC patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the UC […]
RealTime Dynamix™: Multiple Sclerosis US Q2
The Multiple Sclerosis (MS) market is more dynamic and complex than ever with several disease-modifying therapies (DMTs) currently available and a potential game-changer entry, in the form of Roche/Genentech’s Ocrevus (ocrelizumab), approved by the FDA on March 28, 2017. RealTime Dynamix™: Multiple Sclerosis allows marketing professionals to keep abreast and react to these market changes […]
RealTime Dynamix™: Psoriasis US Q2
The Psoriasis market continues to grow, driven by a growing treatment population and the continued uptake of biologics and advanced therapies. In particular, the IL-17 class shows rapid growth, with both Cosentyx (Novartis) and 2016 launched Taltz from Eli Lilly. Tracking the interplay of these two highly regarded treatments will be central to the 2017 […]
RealTime Dynamix™: Rheumatoid Arthritis US Q2
The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of biosimilars present an […]
RealTime Dynamix™: Bone and Mineral US Q2
The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients.Current therapeutic options have multiple limitations and are associated with poor adherence. Recent launches of iron-based, non-calcium phosphate binders have not measurably shifted the market. This monthly report […]
RealWorld Dynamix™: Biologic Switching in IBD US 2017
Ulcerative Colitis (UC) and Crohn’s disease (CD) are common inflammatory bowel diseases, currently affecting the lives of 1.4 million Americans. The introduction of biologics has changed the face of treatment for moderate to severe patients, and biologic switching in both UC and CD over the past 12 months is predictive of future market shape and […]
Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration
IL-17s stop Janssen’s Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition is looming – according to a recent study by Spherix Global Insights CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ — Spherix Global Insights has just released the results of two independent surveys of 200 rheumatologists and […]
